CSL Behring News)

Global Newsroom

Recent News Releases

For investor-related news, see our ASX releases on our parent company's website: CSL.com.

COVID-19 Update
27 Mar 2020

CSL continues to provide medicines to patients around the world.

University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
13 Feb 2020

Philadelphia, Pa

Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative

PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
11 Feb 2020


CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease

Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity
21 Jan 2020

King of Prussia, Pa

This year’s rankings based on independent survey of more than 60,000 U.S. employees across industries

Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference
09 Jan 2020

Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.

King of Prussia, Pa.

CSL Continues to Advance R&D Capabilities
04 Dec 2019

Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing

Sydney, Australia

Harvard Business Review Names Paul Perreault Among Best Performing CEOs in the World
24 Oct 2019

King of Prussia, Pa.

Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings

CSL Behring Continues to Deliver on its Promise to Alpha1 Patients at the 29th Annual European Respiratory Society Congress
27 Sep 2019

• Focuses on Patients Through Disease Awareness Support Activities
• Hosts Patient-Focused Symposium on Alpha 1 Management

CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
01 Jul 2019

Melbourne, Australia

- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted

CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
20 Jun 2019

Genoa, Italy

- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients.

- Presentations include new analysis from the PATH (Polyneuropathy and Treatment with Hizentra) study, the largest clinical trial in CIDP.

Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
16 May 2019

Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May

CSL Names Paul McKenzie as Chief Operating Officer
15 May 2019

Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.

Global Biotherapeutics Leader CSL Behring Opens Regional Headquarters at Dubai Science Park
09 Apr 2019

Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE

Japan’s Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
26 Mar 2019

CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®

CSL Behring Extends Support of World Federation of Hemophilia Programs
04 Feb 2019

Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness

CSL Named One of the Best Employers in the US for Diversity
16 Jan 2019

Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019

Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9
07 Jan 2019

CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.

Resources for Media

Fact Sheet           

At-a glance Facts and Figures About CSL Behring    

Brand Center           

Logos, Design Guidelines and more. (Registration required)

See how we are Driven by Our Promise in our 16-page Corporate Brochure.                        

Want to know more about how we are sharing stories of biotech's promise?

Read Vita

CSL Behring Media Contacts

Natalie de Vane

Corporate Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4468

Jennifer Purdue

Hematology & Thrombosis, Respiratory and Transplant Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4802

Dana Lynch

Immunology & Neurology Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4545

Faraz Kermani

Corporate Inquiries, Europe
Hattersheim am Main, Hesse, Germany
Phone: +49 69 305 17169

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 6421 39-5972

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

CSL Plasma:
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.

Archived News Releases

Get our latest Vita stories in your inbox

First name
Last name


You have now been added
to the CSL Behring Vita list